Brainstorm Cell Therapeutics Inc
$ 0.85
-2.42%
21 Apr - close price
- Market Cap 9,600,300 USD
- Current Price $ 0.85
- High / Low $ 0.87 / 0.81
- Stock P/E N/A
- Book Value -0.91
- EPS -1.11
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -4.36 %
- ROE -11.22 %
- 52 Week High 1.92
- 52 Week Low 0.46
About
Brainstorm Cell Therapeutics Inc., a biotechnology company, is dedicated to the development and commercialization of autologous cell therapies for the treatment of neurodegenerative diseases. The company is headquartered in New York, New York.
Analyst Target Price
$17.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-14 | 2025-08-14 | 2025-05-12 | 2025-03-31 | 2024-11-05 | 2024-08-14 | 2024-04-01 | 2023-12-31 | 2023-11-14 | 2023-08-14 | 2023-05-15 |
| Reported EPS | -0.13 | -0.19 | -0.34 | -0.4841 | -0.51 | -0.51 | -0.04 | -0.04 | -1.5 | -0.03 | -0.27 | -0.14 |
| Estimated EPS | -0.43 | -0.48 | -0.44 | -0.97 | -0.27 | -0.7 | -0.04 | -0.07 | -1.65 | -0.14 | -0.15 | -0.16 |
| Surprise | 0.3 | 0.29 | 0.1 | 0.4859 | -0.24 | 0.19 | 0 | 0.03 | 0.15 | 0.11 | -0.12 | 0.02 |
| Surprise Percentage | 69.7674% | 60.4167% | 22.7273% | 50.0928% | -88.8889% | 27.1429% | 0% | 42.8571% | 9.0909% | 78.5714% | -80% | 12.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCLI
2026-02-15 20:28:01
Brainstorm Cell Therapeutics (BCLI) has secured $1 million in a private placement financing round with an accredited investor. The deal, split into two closings, involves common stock and pre-funded warrants, along with common stock purchase warrants exercisable at $1.00 per share. The company plans to use the net proceeds for working capital, while analysts currently rate BCLI as a Hold with a $0.61 price target, citing weak financial performance and ongoing dilution risks.
2026-02-13 21:57:36
Brainstorm Cell Therapeutics (BCLI) has closed the first half of a $1 million private placement, with the second half scheduled in 30 days. The deal involves common stock and pre-funded warrants, with proceeds intended for working capital. TipRanks' AI Analyst, Spark, rates BCLI as Neutral due to weak financial performance and ongoing risks, despite the new financing providing some support.
2026-02-13 21:57:20
Brainstorm Cell Therapeutics (BCLI) has entered into a Securities Purchase Agreement with an accredited investor for a private placement totaling $1.0 million. This placement involves common stock and pre-funded warrants, with shares priced at $0.60 and pre-funded warrants at $0.5995. The net proceeds from this agreement, which closed its first phase on February 9, 2026, will be used for working capital.
2026-01-09 21:11:15
Brainstorm Cell Therapeutics (BCLI) has secured three unsecured note financings with institutional investors to enhance its liquidity and operational support. These agreements include a $94,300 promissory note with Vanquish Funding Group, a $94,875 convertible note with Quick Capital, and a $140,000 convertible note with Auctus Fund. The notes carry various maturity dates and terms, providing Brainstorm Cell Therapeutics with proceeds to strengthen its financial position.
2025-12-16 12:55:00
The cell therapy manufacturing sector is experiencing significant growth, with the regenerative medicine market projected to reach $403.86 billion by 2032. This article highlights five companies – Avant Technologies, ProKidney Corp., Mesoblast Limited, Lineage Cell Therapeutics, and BrainStorm Cell Therapeutics – that are at the forefront of this industrial transformation. These companies are advancing innovative cell-based therapies for conditions like diabetes, kidney disease, and neurodegenerative disorders, utilizing technologies such as cell encapsulation to overcome historical treatment challenges.
2025-11-01 22:32:05
BrainStorm Cell Therapeutics announced its second quarter 2025 financial results and provided a corporate update, focusing on the progression of its NurOwn® clinical development plan for ALS. Key updates include FDA clearance to initiate the Phase 3b trial, ongoing discussions with clinical sites and CDMO partners, and encouraging survival data from the NurOwn Expanded Access Program. The company also addressed the Citizen Petition to the FDA and detailed its financial performance for the quarter, including cash, R&D expenditures, and net loss.
